{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:00:20Z","timestamp":1725454820069},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:00:00Z","timestamp":1401753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0096600","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T20:20:57Z","timestamp":1401826857000},"page":"e96600","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and Efficacy of Gammaplex\u00ae in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075)"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00504075","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Clive H.","family":"Dash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate R.","family":"Gillanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret E.","family":"Stratford Bobbitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernie W.","family":"Gascoigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha J.","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"DB Cines","year":"2002","journal-title":"New Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"JN George","year":"1996","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","year":"2003","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V89.4.1464","article-title":"Acute idiopathic thrombocytopenic purpura management in childhood","volume":"89","author":"GR Buchanan","year":"1997","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"JE Portielje","year":"2001","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2257.2004.00591.x","article-title":"Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center","volume":"26","author":"J Zimmer","year":"2004","journal-title":"Clin Lab Haematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.67.4.453","article-title":"Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura","volume":"67","author":"SJ Woerner","year":"1981","journal-title":"Pediatrics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"P Imbach","year":"1981","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.480","article-title":"Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura","volume":"62","author":"JB Bussel","year":"1983","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1423-0410.1987.tb03029.x","article-title":"Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature","volume":"52","author":"JB Bussel","year":"1987","journal-title":"Vox Sang"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH03-10-0650","article-title":"IGIV, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life","volume":"91","author":"JB Bussel","year":"2004","journal-title":"Thromb and Haemost"},{"key":"ref12","first-page":"181","article-title":"Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura","volume":"Med76","author":"RR Carroll","year":"1984","journal-title":"Am J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0002-9343(84)90340-1","article-title":"Intravenous gamma globulin in the treatment of chronic idiopathic thrombocytopenic purpura in adults","volume":"76","author":"A Oral","year":"1984","journal-title":"Am J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0002-9343(84)90341-3","article-title":"Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children","volume":"76","author":"I Warrier","year":"1984","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3476(83)80608-8","article-title":"Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy","volume":"103","author":"JB Bussel","year":"1983","journal-title":"J Pediatr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(87)90546-8","article-title":"Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults","volume":"83","author":"R Kurlander","year":"1987","journal-title":"Am J Med"},{"key":"ref17","unstructured":"Medicines and Healthcare products Regulatory Agency (2009) Safe guarding public health dossier for Gammaplex (PL08801\/0053). Available: http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con065781.pdf<\/ext-link>"},{"key":"ref18","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"S Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"D Provan","year":"2010","journal-title":"Blood"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref21","unstructured":"European Medicines Agency (2010) Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). EMA\/CHMP\/BPWP\/94033\/2007 rev. 2. London 22 July 2010. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500004766.pdf<\/ext-link>"},{"key":"ref22","first-page":"37","article-title":"Nonparametric confidence limits for survival probabilities and median survival time","volume":"66","author":"R Simon","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"ref23","unstructured":"US.Department of Health and Human Services, National Institutes of Health and National Cancer Institute (2007) Common Terminology Criteria for Adverse Events (CTCAE), Version 3."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0096600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:10:16Z","timestamp":1649193016000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0096600"}},"subtitle":[],"editor":[{"given":"John W.","family":"Glod","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0096600","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}